Slated for a Dec. 26 decision on Cytokinetics’ aficamten, the FDA has delivered an early Christmas present, awarding the South San Francisco biotech its first U.S. nod since its 1997 founding. | ...

Scientists develop new blood test to identify individuals at high risk of developing hypertrophic cardiomyopathy, most common ...

The FDA has approved aficamten (Myqorzo; Cytokinetics), a cardiac myosin inhibitor, for adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). 1 ...

The FDA on Friday approved aficamten (Myqorzo) for symptomatic obstructive hypertrophic cardiomyopathy (HCM), drugmaker ...

Alnylam Canada ULC is pleased to announce that Health Canada has issued a Notice of Compliance (NOC) authorizing AMVUTTRA® (vutrisiran) for the treatment of cardiomyopathy in adult patients with ...

Mean change in UEC total score from the start of the Phase2/3 study (Week 0) to the final evaluation time point (Week 120) of the extension study. Closed circle and solid line, SA-ER/SA-ER group; open ...

Final Decision from European Commission Expected in Q1 2026SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- Cytokinetics, ...

Considering taking a vitamin or supplement to treat Vitamin D Deficiency-Related Proximal Myopathy? Below is a list of common natural remedies used to treat or reduce the symptoms of Vitamin D ...

DelveInsight’s, “Obesity - Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug ...

Please provide your email address to receive an email when new articles are posted on . In patients with nonobstructive hypertrophic cardiomyopathy, treatment with mavacamten was well tolerated and ...

SAN ANTONIO – Marcus and Allison O’Sullivan are a young military couple with three children -- 8-year-old Brandon, 5-year-old Zack, and 3-year-old Aubrey. Like many others, life was seemingly normal ...